ENDRA Life Sciences (NASDAQ:NDRA) Trading Down 1.8% – Here’s Why

ENDRA Life Sciences Inc. (NASDAQ:NDRA)’s stock price dropped 1.8% during mid-day trading on Tuesday . The stock traded as low as $4.72 and last traded at $4.78. Approximately 8,693 shares were traded during trading, a decline of 71% from the average daily volume of 29,561 shares. The stock had previously closed at $4.87.

Analysts Set New Price Targets

Separately, Wall Street Zen downgraded shares of ENDRA Life Sciences from a “hold” rating to a “sell” rating in a report on Saturday, August 16th. One equities research analyst has rated the stock with a Buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $50.00.

ENDRA Life Sciences Trading Down 1.8%

The company has a market cap of $3.59 million, a P/E ratio of -0.14 and a beta of -0.14. The stock’s 50-day moving average price is $5.33 and its 200-day moving average price is $4.40.

ENDRA Life Sciences (NASDAQ:NDRA) last released its quarterly earnings data on Thursday, August 14th. The company reported ($1.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.27) by $0.56. On average, research analysts anticipate that ENDRA Life Sciences Inc. will post -47.46 earnings per share for the current fiscal year.

About ENDRA Life Sciences

ENDRA Life Sciences Inc develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion.